Researchers presented a poster at Maui Derm NP+PA Summer, discussing the use of the oral tyrosine kinase 2 inhibitor, deucravacitinib, in patients with moderate-to-severe psoriasis. The phase 3 clinical trials, POETYK PSO-1 and PSO-2, involved participants being randomly assigned to receive deucravacitinib, placebo, or apremilast. In both trials, the group receiving deucravacitinib experienced significant improvement Static Physician’s Global Assessment scores of 0 or 1 and a ≥75% reduction from baseline in Psoriasis Area and Severity Index Score. Participants also showed considerable improvement in Psoriasis Symptoms and Signs Diary total scores and Dermatology Life Quality Index total scores compared with the placebo or apremilast groups.
The study findings suggest that deucravacitinib treatment leads to skin clearance, symptom reduction, and better quality of life in patients with moderate-to-severe psoriasis. A higher clinical response was associated with a more significant improvement in patient-reported outcomes.
Reference: Raglin H. Plaque Psoriasis Symptoms Improved With Deucravacitinib Treatment. Dermatology Times. Published July 5, 2023. Accessed July 28, 2023. https://www.dermatologytimes.com/view/plaque-psoriasis-symptoms-improved-with-deucravacitnib-treatment
